Literature DB >> 8703225

Autism in Angelman syndrome: a population-based study.

S Steffenburg1, C L Gillberg, U Steffenburg, M Kyllerman.   

Abstract

The aim of this study was to examine the prevalence of angelman syndrome in prepubertal school-aged children and analyze its comorbidity with autistic disorder. A clinical/psychiatric evaluation of a population-based sample of 6- to 13-year-old mentally retarded children with active epilepsy was performed. Four individuals in a total population of almost 49,000 children conformed to the clinical diagnosis of Angelman syndrome. Two of these had a typical microdeletion at chromosome 15q11-13. The minimum prevalence of Angelman syndrome was estimated at 0.008% (1: 12,000) in the examined age group. All 4 children with Angelman syndrome met full behavioral criteria for the diagnosis of autistic disorder/childhood autism. It is concluded that Angelman syndrome is uncommon, but more frequent than previously estimated. The diagnosis should be considered in all patients with combined autistic disorder, severe mental retardation, and epilepsy. The implications of the possible association of Angelman syndrome and autism are discussed.

Entities:  

Mesh:

Year:  1996        PMID: 8703225     DOI: 10.1016/0887-8994(96)00011-2

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  56 in total

1.  The human aminophospholipid-transporting ATPase gene ATP10C maps adjacent to UBE3A and exhibits similar imprinted expression.

Authors:  L B Herzing; S J Kim; E H Cook ; D H Ledbetter
Journal:  Am J Hum Genet       Date:  2001-05-11       Impact factor: 11.025

Review 2.  The screening and diagnosis of autistic spectrum disorders.

Authors:  P A Filipek; P J Accardo; G T Baranek; E H Cook; G Dawson; B Gordon; J S Gravel; C P Johnson; R J Kallen; S E Levy; N J Minshew; S Ozonoff; B M Prizant; I Rapin; S J Rogers; W L Stone; S Teplin; R F Tuchman; F R Volkmar
Journal:  J Autism Dev Disord       Date:  1999-12

Review 3.  Specific genetic disorders and autism: clinical contribution towards their identification.

Authors:  David Cohen; Nadège Pichard; Sylvie Tordjman; Clarisse Baumann; Lydie Burglen; Elsa Excoffier; Gabriela Lazar; Philippe Mazet; Clément Pinquier; Alain Verloes; Delphine Héron
Journal:  J Autism Dev Disord       Date:  2005-02

4.  Associations of hypomelanotic skin disorders with autism: Do they reflect the effects of genetic mutations and epigenetic factors on vitamin-D metabolism in individuals at risk for autism?

Authors:  Muideen O Bakare; Kerim M Munir; Dennis K Kinney
Journal:  Hypothesis (Macon)       Date:  2011-04-16

Review 5.  Chromosomal disorders and autism.

Authors:  C Gillberg
Journal:  J Autism Dev Disord       Date:  1998-10

6.  Maternal origin of inv dup(15) chromosomes in infantile autism.

Authors:  T Martinsson; T Johannesson; M Vujic; A Sjöstedt; S Steffenburg; C Gillberg; J Wahlström
Journal:  Eur Child Adolesc Psychiatry       Date:  1996-12       Impact factor: 4.785

7.  Social-emotional processing in nonverbal individuals with Angelman syndrome: evidence from brain responses to known and novel names.

Authors:  A P Key; D Jones
Journal:  J Intellect Disabil Res       Date:  2018-11-23

Review 8.  Autism: in search of susceptibility genes.

Authors:  Janine A Lamb; Jeremy R Parr; Anthony J Bailey; Anthony P Monaco
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 9.  Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms.

Authors:  Renzo Guerrini; Romeo Carrozzo; Roberta Rinaldi; Paolo Bonanni
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder.

Authors:  Timothy M DeLorey; Peyman Sahbaie; Ezzat Hashemi; Gregg E Homanics; J David Clark
Journal:  Behav Brain Res       Date:  2007-09-14       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.